FR0011472943
© Globe Newswire
03.02.2026
VALN
LISTED
NASDAQ
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
News Preview
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva’s single-shot chikungunya vaccine, IXCHIQ®. Th...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
VALN
LISTED
NASDAQ
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
News Preview
Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ®, in the United States, following sus...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2026
VALN
LISTED
NASDAQ
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
News Preview
Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, Januar...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
08.01.2026
VALN
LISTED
NASDAQ
Valneva SE - Declaration of voting rights - December 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
31.12.2025
VALN
LISTED
NASDAQ
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
News Preview
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
VALN
LISTED
NASDAQ
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
News Preview
Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 chi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: November 30, 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
VALN
LISTED
NASDAQ
Valneva to Further Consolidate its Operations in France
News Preview
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company’s ongoing efforts to increase operational effectiveness and position Valneva for long-term success. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
VALN
LISTED
NASDAQ
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
News Preview
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (mo...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
VALN
LISTED
NASDAQ
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
News Preview
Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valn...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
VALN
LISTED
NASDAQ
VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
VALN
LISTED
NASDAQ
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
News Preview
Immune response successfully improved with second generation vaccine candidate...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.10.2025
VALN
LISTED
NASDAQ
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
News Preview
Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
VALN
LISTED
NASDAQ
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
News Preview
Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharmakon Advisors, LP. An initial tranche of $215 million will be used to repay in full the Company’s...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: September 30, 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
VALN
LISTED
NASDAQ
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
News Preview
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: August 31, 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
VALN
LISTED
NASDAQ
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
News Preview
Saint-Herblain (France), September 3rd, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. The strong anamnestic immune response and favorable safety profile following a third booster dose were consistent with those reported...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
VALN
LISTED
NASDAQ
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
News Preview
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.08.2025
VALN
LISTED
NASDAQ
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
News Preview
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement a...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2025
VALN
LISTED
NASDAQ
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
News Preview
Saint-Herblain (France), August 12, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025 financial guidance. The half year financial report, including the condensed consolidated inter...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
VALN
LISTED
NASDAQ
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
News Preview
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in th...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2025
VALN
LISTED
NASDAQ
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
News Preview
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EM...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: June 30, 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
VALN
LISTED
NASDAQ
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
News Preview
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
VALN
LISTED
NASDAQ
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
News Preview
Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Annual General Meeting held today in Lyon, France....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
VALN
LISTED
NASDAQ
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
News Preview
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 25, 2025 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
VALN
LISTED
NASDAQ
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
News Preview
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause in the use of Valneva’s single-d...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: April 30, 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
VALN
LISTED
NASDAQ
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
News Preview
Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Comp...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.04.2025
VALN
LISTED
NASDAQ
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
News Preview
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.04.2025
VALN
LISTED
NASDAQ
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
News Preview
Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dos...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
VALN
LISTED
NASDAQ
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
News Preview
Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 inf...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
VALN
LISTED
NASDAQ
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
News Preview
Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, cur...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
VALN
LISTED
NASDAQ
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
News Preview
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration statement on Form F-3, filed on March 25, 2025 with the U.S. Securities and Exchange Commission (“SEC...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
VALN
LISTED
NASDAQ
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
News Preview
Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exc...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
VALN
LISTED
NASDAQ
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
News Preview
Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
VALN
LISTED
NASDAQ
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
News Preview
Saint-Herblain (France), March 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its consolidated financial results for the year ended December 31, 2024 and provided key corporate updates and guidance for its future results. The consolidated financial results2 are available on the Company’s websi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: February 28, 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
VALN
LISTED
NASDAQ
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
News Preview
Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference,...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
VALN
LISTED
NASDAQ
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
News Preview
Saint-Herblain (France), February 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2024 revenue and cash results1 and provided a 2025 outlook. The Company will publish its 2024 audited consolidated financial statements and host an analyst call on March 20, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
VALN
LISTED
NASDAQ
Shareholding declaration Valneva SE - January 2025
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.02.2025
VALN
LISTED
NASDAQ
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
News Preview
Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vacci...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2025
VALN
LISTED
NASDAQ
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
News Preview
Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
VALN
LISTED
NASDAQ
VALNEVA Declaration of shares and voting rights: December 31, 2024
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
VALN
LISTED
NASDAQ
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India
News Preview
Saint-Herblain (France), Pune, (India), December 19, 2024 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2024
VALN
LISTED
NASDAQ
VALNEVA - Declaration of shares and voting rights: November 30, 2024
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
VALN
LISTED
NASDAQ
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
News Preview
Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne disease chikungunya in The British Medical Journal (BMJ), one of the world’s leading peer-reviewed medical journals....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
VALN
LISTED
NASDAQ
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
News Preview
Saint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
VALN
LISTED
NASDAQ
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
News Preview
Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
VALN
LISTED
NASDAQ
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
News Preview
Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
VALN
LISTED
NASDAQ
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
News Preview
Nine-Month Key Financial Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
VALN
LISTED
NASDAQ
VALNEVA - Declaration of shares and voting rights: October 31, 2024
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
VALN
LISTED
NASDAQ
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
News Preview
Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2024
VALN
LISTED
NASDAQ
Valneva Hosts Investor Day in New York City
News Preview
Live event and webcast TODAY at 10 AM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.10.2024
VALN
LISTED
NASDAQ
Valneva SE - Declaration of shares and voting rights - September 30, 2024
News Preview
VALNEVA...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2024
VALN
LISTED
NASDAQ
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
News Preview
Saint Herblain (France), October 3, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, NY on Thursday, October 10, 2024 at 10:00 AM ET (4:00 pm CET). The meeting will be conducted in a hybrid way – in person and webcast....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
VALN
LISTED
NASDAQ
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
News Preview
To potentially include adolescents and antibody persistence up to two years...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.09.2024
VALN
LISTED
NASDAQ
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
News Preview
Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2024
VALN
LISTED
NASDAQ
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
News Preview
Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6 million new ordinary shares (the “Offer Shares”) at a price of €2.66 per Offer Share to certain categories of...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
